{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:53:42Z","timestamp":1773906822976,"version":"3.50.1"},"reference-count":31,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"name":"Unitaid"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2021,5,31]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recent World Health Organization guidance on drug-resistant tuberculosis treatment de-prioritised injectable agents, in use for decades, and endorsed all-oral longer regimens. However, questions remain about the role of the injectable agent, particularly in the context of regimens using new and repurposed drugs. We compared the effectiveness of an injectable-containing regimen to that of an all-oral regimen among patients with drug-resistant tuberculosis who received bedaquiline and\/or delamanid as part of their multidrug regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with a positive baseline culture were included. 6-month culture conversion was defined as two consecutive negative cultures collected &gt;15\u2005days apart. We derived predicted probabilities of culture conversion and relative risk using marginal standardisation methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Culture conversion was observed in 83.8% (526 out of 628) of patients receiving an all-oral regimen and 85.5% (425 out of 497) of those receiving an injectable-containing regimen. The adjusted relative risk comparing injectable-containing regimens to all-oral regimens was 0.96 (95% CI 0.88\u20131.04). We found very weak evidence of effect modification by HIV status: among patients living with HIV, there was a small increase in the frequency of conversion among those receiving an injectable-containing regimen, relative to an all-oral regimen, which was not apparent in HIV-negative patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Among individuals receiving bedaquiline and\/or delamanid as part of a multidrug regimen for drug-resistant tuberculosis, there was no significant difference between those who received an injectable and those who did not regarding culture conversion within 6\u2005months. The potential contribution of injectable agents in the treatment of drug-resistant tuberculosis among those who were HIV positive requires further study.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.04345-2020","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T16:40:16Z","timestamp":1623948016000},"page":"2004345","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings"],"prefix":"10.1183","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-8355","authenticated-orcid":false,"given":"Palwasha Y.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly F.","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Hewison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwonjune J.","family":"Seung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-9063","authenticated-orcid":false,"given":"Helena","family":"Huerga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney","family":"Atwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munira","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanha","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Manzur-ul-Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-6286","authenticated-orcid":false,"given":"Luan N.Q.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid","family":"Lecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalkidan","family":"Yae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serik","family":"Kozhabekov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meseret","family":"Tamirat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Gelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stalz C.","family":"Vilbrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kikvidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamil","family":"Faqirzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullaat","family":"Kadyrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Skrahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Mesic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Avagyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3602-5950","authenticated-orcid":false,"given":"Uzma","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3455-658X","authenticated-orcid":false,"given":"Carole D.","family":"Mitnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"2024102102325828000_59.1.2004345.1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1473-3099(17)30247-5","article-title":"Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study","volume":"17","author":"Sharma","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2024102102325828000_59.1.2004345.2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S2213-2600(19)30263-2","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"7","author":"Dheda","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102102325828000_59.1.2004345.3","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13143"},{"key":"2024102102325828000_59.1.2004345.4","unstructured":"World Health Organization (WHO) . WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva, WHO, 2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/311389\/9789241550529-eng.pdf?ua=1"},{"key":"2024102102325828000_59.1.2004345.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00044812"},{"key":"2024102102325828000_59.1.2004345.6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02586-16"},{"key":"2024102102325828000_59.1.2004345.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"2024102102325828000_59.1.2004345.8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1473-3099(19)30424-4","article-title":"Value of observational data for multidrug-resistant tuberculosis","volume":"19","author":"Rodriguez","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024102102325828000_59.1.2004345.9","doi-asserted-by":"crossref","first-page":"18001528","DOI":"10.1183\/13993003.01528-2018","article-title":"High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen","volume":"52","author":"Ndjeka","year":"2018","journal-title":"Eur Respir J"},{"key":"2024102102325828000_59.1.2004345.10","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/cid\/ciy727","article-title":"Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study","volume":"68","author":"Zhao","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024102102325828000_59.1.2004345.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1874ST"},{"key":"2024102102325828000_59.1.2004345.12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12879-019-4378-4","article-title":"The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens","volume":"19","author":"Khan","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2024102102325828000_59.1.2004345.13","unstructured":"World Health Organization (WHO) . WHO Treatment Guidelines for Drug-Resistant Tuberculosis \u2013 2016 Update. Geneva, World Health Organization, 2016. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/250125\/9789241549639-eng.pdf?sequence=1"},{"key":"2024102102325828000_59.1.2004345.14","unstructured":"endTB Consortium . endTB Clinical and Programmatic Guide for Patient Management with New TB Drugs. Version 4. 2018. www.endtb.org\/sites\/default\/files\/2018-04\/Guide%20for%20New%20TB%20Drugs%20Version%204.0.pdf Date last accessed: 12 March 2020."},{"key":"2024102102325828000_59.1.2004345.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0224-2"},{"key":"2024102102325828000_59.1.2004345.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"2024102102325828000_59.1.2004345.17","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200105000-00011"},{"key":"2024102102325828000_59.1.2004345.18","unstructured":"Rothman KJ , Greenland S , Lash TL . Modern Epidemiology. 3rd Edn. Philadelphia, Lippincott Williams & Wilkins, 2008."},{"key":"2024102102325828000_59.1.2004345.19","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu029"},{"key":"2024102102325828000_59.1.2004345.20","unstructured":"Department of Health, Republic of South Africa . New Bedaquiline Data Shows Reduction in TB Mortality Cases. 2018. https:\/\/hivandmore.de\/aktuell\/2018-06\/New-Bedaquiline-data-shows-reduction-in-TB-mortality-cases.pdf"},{"key":"2024102102325828000_59.1.2004345.21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102102325828000_59.1.2004345.22","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0944"},{"key":"2024102102325828000_59.1.2004345.23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/rccm.202001-0135OC","article-title":"Culture conversion in patients treated with bedaquiline and\/or delamanid: a prospective multicountry study","volume":"203","author":"Franke","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102102325828000_59.1.2004345.24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/QAI.0000000000000763","article-title":"Raised venous lactate and markers of intestinal translocation are associated with mortality among in-patients with HIV-associated TB in rural South Africa","volume":"70","author":"Subbarao","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024102102325828000_59.1.2004345.25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(19)30106-9","article-title":"The STREAM trial: missed opportunities and lessons for future clinical trials","volume":"19","author":"Loveday","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024102102325828000_59.1.2004345.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811867"},{"key":"2024102102325828000_59.1.2004345.27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5588\/ijtld.17.0830","article-title":"Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection","volume":"22","author":"Hong","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102102325828000_59.1.2004345.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00061-2017"},{"key":"2024102102325828000_59.1.2004345.29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4269\/ajtmh.18-0985","article-title":"What's next for the standard short-course regimen for treatment of multidrug-resistant tuberculosis","volume":"100","author":"Campbell","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2024102102325828000_59.1.2004345.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001932"},{"key":"2024102102325828000_59.1.2004345.31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.5588\/ijtld.20.0076","article-title":"Time for a change: considering regimen changes in analyses of observational MDR\/RR-TB treatment cohort data","volume":"24","author":"Franke","year":"2020","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.04345-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:45:15Z","timestamp":1740375915000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.04345-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,20]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1183\/13993003.04345-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.04345-2020","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]}}}